Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Acta Radiologica (Stockholm, Sweden : 1987)|April 19, 2011
Physicians' knowledge about ionizing radiation and radiological imaging techniques: a cross-sectional surveyAylin Yucel, Cansu Alyesil, Saadet Sim
Melanoma Research|May 1, 2024
Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literatureAhmet Anil Ozluk, Damla Gunenc, Saadet Sim Yildirim, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer ConsortiumMusa Barış Aykan, Hatice Bölek, Emre Yekedüz, et al.
Clinical Genitourinary Cancer|December 22, 2024
Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) DatabaseHatice Bölek, Elif Sertesen, Omer Faruk Kuzu, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 15, 2025
Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, et al.
BMC Cancer|July 27, 2025
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinomaOmer Faruk Kuzu, Hatice Bolek, Elif Sertesen Camoz, et al.
The Oncologist|June 27, 2025
The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer ConsortiumElif Sertesen Camoz, Hatice Bolek, Omer Faruk Kuzu, et al.
Immunotherapy|July 4, 2025
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) studySerhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, et al.
Medicine|July 26, 2024
The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancerHasan Cagri Yildirim, Mustafa Buyukkor, Gözde Kavgaci, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 13, 2026
Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG)Ozden Demir, Bulent Cetin, Ali Alkan, et al.
Pageof 2